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The aldehyde dehydrogenase 2 (ALDH2) polymorphism rs671 (Glu504Lys) causes
ALDH2 inactivation and adverse acetaldehyde exposure among Asians, but little is
known of the association between alcohol consumption and rs671 and ovarian can-
cer (OvCa) in Asians. We conducted a pooled analysis of Asian ancestry participants
in the Ovarian Cancer Association Consortium. We included seven case-control
studies and one cohort study comprising 460 invasive OvCa cases, 37 borderline
mucinous OvCa and 1274 controls of Asian descent with information on recent
alcohol consumption. Pooled odds ratios (OR) with 95% confidence intervals (CI) for
OvCa risk associated with alcohol consumption, rs671 and their interaction were
estimated using logistic regression models adjusted for potential confounders. No
significant association was observed for daily alcohol intake with invasive OvCa (OR
comparing any consumption to none = 0.83; 95% CI = 0.58-1.18) or with individual
histotypes. A significant decreased risk was seen for carriers of one or both Lys alle-
les of rs671 for invasive mucinous OvCa (OR = 0.44; 95% CI = 0.20-0.97) and for
invasive and borderline mucinous tumors combined (OR = 0.48; 95% CI = 0.26-
0.89). No significant interaction was observed between alcohol consumption and
rs671 genotypes. In conclusion, self-reported alcohol consumption at the quantities
estimated was not associated with OvCa risk among Asians. Because the rs671 Lys
allele causes ALDH2 inactivation leading to increased acetaldehyde exposure, the
observed inverse genetic association with mucinous ovarian cancer is inferred to
mean that alcohol intake may be a risk factor for this histotype. This association will
require replication in a larger sample.
K E YWORD S
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1 | INTRODUCTION
Ovarian cancer is one of the most common gynecological cancers.
Approximately 239 000 females developed a new ovarian cancer in
2012 and 152 000 women died globally of the disease.1 Despite its
high incidence and mortality, the etiology is not fully understood;
however, established epidemiological risk factors for ovarian cancer
include age, parity, oral contraceptive use, tubal ligation, and inher-
ited germline mutations in BRCA1 and BRCA2.2,3
Alcohol consumption is one of the possible modifiable risk fac-
tors for ovarian cancer. Several studies have investigated the associ-
ation between alcohol drinking and ovarian cancer risk and reported
inconsistent results.4-14 To resolve this inconsistency, pooled analy-
ses have been conducted.5,15-17 These studies failed to show a clear
association between alcohol drinking and ovarian cancer risk overall;
however, some showed a different trend in associations with alcohol
by histological subtypes,16,17 suggesting different biological etiologies
according to histology.18
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Generally, a differential distribution pattern of the histological
subtypes of epithelial ovarian cancer has been observed across eth-
nicities and countries.19 Among Asian women, the prevalence of ser-
ous adenocarcinoma is relatively low, whereas that of clear cell
adenocarcinoma is higher, compared with ovarian cancers among
women of European descent. Furthermore, Asian women are likely
to have different genetic and sociocultural backgrounds, which
includes less alcohol consumption,20 lower prevalence of hormone
therapy use21 and a different distribution of the aldehyde dehydro-
genase 2 (ALDH2) polymorphism Glu504Lys (rs671).22 The rs671
polymorphism in ALDH2 is more prevalent in East-Asian populations
(minor allele frequency [MAF] in HapMap-JPT = 0.24, and 0.15 in
HapMap-HCB)22 and absent among Europeans (MAF HapMap-
CEU = 0). The Lys allele of rs671 is strongly associated with inacti-
vation of ALDH2,23,24 which results in prolonged exposure to the
intermediate metabolite acetaldehyde, a potential carcinogen in vari-
ous organs.25-30 To our knowledge, there are no studies exploring
the association between rs671 in ALDH2 and ovarian cancer risk,
particularly among Asian women.
To investigate whether there is an association between alcohol
drinking, the rs671 polymorphism in ALDH2 and ovarian cancer risk,
we conducted a pooled analysis of data from women of Asian ances-
try participating in the Ovarian Cancer Association Consortium
(OCAC).
2 | MATERIALS AND METHODS
2.1 | Study population
We conducted this pooled analysis using seven case-control studies
and one cohort study with information on alcohol consumption from
the OCAC. We included 460 invasive ovarian cancer cases, 37 bor-
derline mucinous tumors and 1274 controls. Other borderline tumors
(n = 23) except mucinous were excluded from the analysis because,
unlike other ovarian histotypes, mutational evidence suggests muci-
nous tumors progress along a multistep continuum from benign to
borderline to invasive tumors.31
Information from the eight studies is summarized in Table 1. All
study participants were of Asian ancestry in Japan [JPN32,33], China
[SWH34], Australia [AUS35], and the USA [DOV,36 HAW,37 NCO,38,39
NEC,40,41 and USC42]. One study was a hospital-based study, six
were population-based studies, and one was a defined cohort study.
Informed consent was obtained from participating subjects in each of
the individual studies, and local human research investigations com-
mittees approved each study. This investigation was approved by a
human research investigations committee at Aichi Cancer Center.
2.2 | Genotyping methods
Genotyping was carried out as part of the Collaborative Oncological
Gene-environment Study (COGS),43 a collaboration between the
OCAC and three other consortia. Full details of selection of single
nucleotide polymorphisms (SNP), array design, genotyping and post-
genotyping quality control have been described elsewhere.44 SNP on
the iCOGS chip were categorized into three categories: (i) selected
on the basis of pooled genome-wide association study data; (ii)
selected for the fine-mapping of published risk loci; and (iii) selected
on the basis of previous analyses or specific hypotheses. SNP rs671
on ALDH2 was a candidate SNP selected on the basis of specific
hypotheses described above.
For the OCAC samples, genotyping of 211 155 SNP in 47 630
samples from 43 individual studies was conducted using a custom
Illumina Infinium array (iCOGS; Illumina, San Diego, CA, USA) across
two centers, of which 44 308 passed quality control. Genotypes
were called using Illumina’s proprietary GenCall algorithm. Standard
quality control measures were applied across all SNP and all samples.
Samples were excluded for any of the following reasons: genotypi-
cally not female XX (XY, XXY or XO); overall call rate <95%; low or
high heterozygosity (P < 106); individuals not concordant with pre-
vious genotyping within the OCAC; individuals where genotypes for
the duplicate sample appeared to be from a different individual;
cryptic duplicates within studies where the phenotypic data indi-
cated that the individuals were different, or between studies where
genotype data indicated samples were duplicates; and samples from
first-degree relatives. We used the program LAMP45 to assign inter-
continental ancestry on the basis of genotype frequencies in the
European, Asian and African populations in OCAC samples. Individu-
als with >20% minority ancestry for the Asian ancestral group were
considered mixed ancestry and excluded based on LAMP analysis.
We then used a set of 37 000 unlinked markers to carry out princi-
pal components analysis within the Asian ancestral group to identify
residual population substructure.46 For the analyses of Asian sub-
jects, we included five principal components as covariates.
2.3 | Alcohol assessment and covariate data
collection
Harmonization of daily alcohol intake across OCAC studies was pre-
viously described.16 Briefly, daily alcohol consumption was estimated
using validated food frequency questionnaires (FFQ) in AUS,47
DOV,48 HAW,49 NEC,50 SWH,51 and USC or from questions regard-
ing alcohol intake embedded in a risk factor questionnaire (NCO,
JPN). The exposure period was the year preceding recruitment (AUS,
HAW, JPN, NEC, SWH, USC) or at the time period approximately 4
(DOV) or 5 (NCO) years before the reference date. Daily alcohol
consumption in grams was determined by summing the product of
frequency of consumption of specified alcoholic beverages (beer,
wine, and other alcoholic beverages, including liquor, Japanese Sake,
Chuuhai and Shochu) by the alcohol content of each beverage using
national estimates of alcohol content for that country. Total alcohol
intake was calculated as the sum of each alcohol intake and used for
the analysis. The AUS, DOV, HAW, and NEC studies provided the
information for white and red wine separately.
Key clinical, demographic and questionnaire data on study sub-
jects (see below) were merged into a common dataset by the coordi-
nating center and checked for consistency.
UGAI ET AL. | 437
T
A
B
L
E
1
Li
st
o
f
pa
rt
ic
ip
at
in
g
st
ud
ie
s
an
d
nu
m
be
r
o
f
su
bj
ec
ts
St
ud
y
ac
ro
ny
m
[r
ef
er
en
ce
#
]
St
ud
y
n
am
e
C
o
un
tr
y
St
ud
y
de
si
gn
C
o
nt
ro
ls
,
N
In
va
si
ve
ca
se
s,
N
B
o
rd
er
lin
e
ca
se
s,
N
Ly
s
al
le
le
fr
eq
ue
nc
y
am
o
ng
in
va
si
ve
ca
se
s
(%
)
Ly
s
al
le
le
fr
eq
ue
nc
y
am
o
ng
co
nt
ro
ls
(%
)
M
ed
ia
n
ag
e
(r
an
ge
),
in
va
si
ve
ca
se
s
M
ed
ia
n
ag
e
(r
an
ge
),
co
nt
ro
ls
P
ro
p
o
rt
io
n
o
f
ev
er
dr
in
ke
rs
am
o
n
g
ca
se
s
(%
)
P
ro
p
o
rt
io
n
o
f
ev
er
d
ri
n
ke
rs
am
o
n
g
co
n
tr
o
ls
(%
)
1
2
7
4
4
6
0
5
9
1
8
.8
2
2
.5
5
4
(2
3
-8
5
)
5
2
.2
(1
9
-8
8
)
1
8
.7
1
0
.5
A
U
S3
5
A
us
tr
al
ia
O
va
ri
an
C
an
ce
r
St
ud
y
&
A
us
tr
al
ia
C
an
ce
r
St
ud
y
(A
O
C
S/
A
C
S)
A
us
tr
al
ia
P
o
pu
la
ti
o
n-
ba
se
d
1
6
2
6
0
9
.6
2
1
.9
4
8
.5
(3
1
-6
3
)
4
9
(2
3
-7
9
)
4
2
.3
3
1
.3
D
O
V
3
6
D
is
ea
se
s
o
f
th
e
O
va
ry
an
d
th
ei
r
E
va
lu
at
io
n
(D
O
V
E
)
U
SA
P
o
pu
la
ti
o
n-
ba
se
d
4
1
4
0
1
0
1
2
.5
8
.5
4
8
.5
(3
5
-7
4
)
5
0
(3
6
-6
9
)
2
4
.0
3
6
.6
H
A
W
3
7
H
aw
ai
i
O
va
ri
an
C
an
ce
r
St
ud
y
U
SA
P
o
pu
la
ti
o
n-
ba
se
d
2
0
4
1
0
3
1
8
1
9
.9
1
9
.1
5
9
(2
8
-8
5
)
5
8
(2
2
-8
8
)
1
4
.1
3
7
.8
JP
N
3
2
,3
3
H
o
sp
it
al
-b
as
ed
E
pi
de
m
io
lo
gi
c
R
es
ea
rc
h
P
ro
gr
am
at
A
ic
hi
(H
E
R
P
A
C
C
)
Ja
pa
n
H
o
sp
it
al
-b
as
ed
8
1
6
7
1
1
2
9
.1
2
9
.0
5
4
(2
3
-7
5
)
5
3
(1
9
-7
4
)
3
6
.7
4
0
.7
N
C
O
3
8
,3
9
N
o
rt
h
C
ar
o
lin
a
O
va
ri
an
C
an
ce
r
St
ud
y
(N
C
O
C
S)
U
SA
P
o
pu
la
ti
o
n-
ba
se
d
5
6
5
0
.0
3
0
.0
4
1
.5
(2
4
-6
1
)
5
6
(4
3
-7
3
)
7
2
.7
4
0
.0
N
E
C
4
0
,4
1
N
ew
E
ng
la
nd
-b
as
ed
C
as
e-
C
o
nt
ro
l
St
ud
y
o
f
O
va
ri
an
C
an
ce
r
(N
E
C
C
)
U
SA
P
o
pu
la
ti
o
n-
ba
se
d
6
1
1
6
1
3
.6
8
.3
3
9
(2
7
-6
1
)
3
9
.5
(3
4
-6
1
)
4
7
.1
5
0
.0
SW
H
3
4
Sh
an
gh
ai
W
o
m
en
’s
H
ea
lt
h
St
ud
y
(S
W
H
S)
C
hi
na
D
ef
in
ed
co
ho
rt
8
6
4
1
3
5
0
2
0
.4
2
3
.8
5
7
.2
(4
3
-8
1
)
5
1
.6
(4
0
-7
1
)
3
.0
2
.5
5
U
SC
4
2
Lo
s
A
ng
el
es
C
o
un
ty
C
as
e-
C
o
nt
ro
l
St
ud
ie
s
o
f
O
va
ri
an
C
an
ce
r
(L
A
C
-C
C
O
C
)
U
SA
P
o
pu
la
ti
o
n-
ba
se
d
5
7
7
2
9
1
3
.9
1
5
.8
4
9
(2
3
-8
4
)
4
7
(2
4
-7
8
)
9
.9
5
.2
6
438 | UGAI ET AL.
2.4 | Data analyses
Differences in categorized demographic variables between the cases
and controls were tested using the chi-squared test except where
there were a large number of missing observations.
To assess the strength of the associations of ALDH2 polymor-
phism and daily alcohol consumption with the risk of invasive ovar-
ian cancer, odds ratios (OR) with 95% confidence intervals (CI) were
estimated using unconditional logistic regression models. The alcohol
consumption analyses used as the reference group women who did
not consume any type of alcoholic beverage. Based on the median
value of grams per day of alcohol consumed (total alcohol and alco-
hol from beer, wine [white, red] and other alcohol) among controls
(7.57 g/d), alcohol consumption was classified into two (none, any
alcohol intake) and three categories (none, up to and including the
median intake, more than the median intake). Models for the main
effect of alcohol were adjusted for age, 5 Asian principal compo-
nents, smoking status (never, ever smokers), and study. Missing val-
ues for covariates were treated as dummy variables in the models.
Other possible confounders were excluded from the multivariate
model as a result of a large number of missing observations. Risk
models associated with total alcohol intake did not include other
alcoholic beverage types. Risk models associated with beer, wine or
liquor intake included all three beverage types and were thus
adjusted for each other. Risk models associated with white or red
wine intake included beer and liquor intake.
OR for the main effect of ALDH2 genotypes on ovarian cancer
risk were adjusted for age, 5 Asian principal components, and study
under both codominant and dominant genetic models using the Glu/
Glu genotype as reference. We conducted stratified analyses by his-
tological subtypes and applied a multinomial logistic regression
model to evaluate heterogeneity for an association of the ALDH2
Lys allele across histological subtypes. Models were compared using
the likelihood-ratio test.
To assess the joint effect of genotype and alcohol intake, we
created four categories combining genotype with alcohol intake:
non-Lys allele carriers and no alcohol intake as a reference group;
non-Lys allele carriers and any alcohol intake; Lys allele carriers and
no alcohol intake; and Lys allele carriers and any alcohol intake.
Even though all study participants were of Asian ancestry,
heterogeneity among studies might affect the results. Therefore, we
repeated all analyses using random effects meta-analyses to calculate
summary study-specific estimates.
P-value <.05 was considered statistically significant. All analyses
were carried out using STATA version 13.1 (Stata Corp., College
Station, TX, USA).
3 | RESULTS
Table 1 shows the distribution of cases and controls, Lys allele fre-
quency, median age and the proportion of ever drinkers for each
study. Median age of cases and controls and Lys allele frequency
varied across the eight studies with NEC showing the lowest allele
frequency of 8.3% and NCO having the highest at 30% among con-
trols. This reflects the diverse composition of participants catego-
rized as “Asian” in these studies (eg, Chinese, Japanese, Korean or
Pilipino). However, the two studies conducted in Asian countries
(JPN and SWH) had relatively similar Lys allele frequencies (29% and
23.8%, respectively). To illustrate, the figures show the results from
superimposing the data from the first two orthogonal principal com-
ponents from over 30 000 unlinked markers from each Asian ances-
try study participant from a single study (blue circles) onto the data
from all Asian ancestry study participants in OCAC (black circles),
and where the black clusters segregated according to country of
genetic origin. In Figure 1, Asian participants from the two Asian
countries, JPN (Japan) and SWH (Shanghai, China), are shown in
panels A and B and participants from two other Asian studies, KRA
(Korea) and CHA (China), are shown in panels C and D. Figure 2
shows that Asian participants from the USC (California) and DOV
(Washington) studies in the USA (panels A and B) had allele frequen-
cies mapping to regions in Japan, China and the Philippines, whereas
Asian participants from the HAW (Hawaii) study had allele frequen-
cies mapping more strongly and, not surprisingly, to regions in Japan
and the Philippines and to a lesser extent to China. Subsequent sta-
tistical models controlled for this variability with the inclusion of five
principal components as covariates. The proportion of ever drinkers
was lower in SWH and USC, compared with other studies.
Demographic characteristics and selected lifestyle habits of study
subjects are shown in Table 2. Distribution of histological subtypes
among invasive ovarian cancer cases was 188 serous (40.9%), 42
mucinous (9.1%), 75 endometrioid (16.3%), and 69 clear cell (15.0%)
adenocarcinomas. Overall, prevalence of the Lys allele carrier was
33.9% of cases and 39.5% of controls. Median total alcohol intake
among controls who consumed alcohol recently was 7.57 g/d. Cases
were more likely to drink alcohol (P < .001). The proportion of ever
smokers was higher among cases. Overall, the median age of cases
and controls was 54.0 and 52.2 years, respectively. A higher propor-
tion of cases compared to controls was observed in the youngest
and oldest age groups. Distribution of other variables (age at menar-
che, use of oral contraception, tubal ligation, low parity, body mass
index [BMI], history of any prior cancer and family history of breast
or ovarian cancer in first-degree relatives) is shown in Table 2 but
should be interpreted cautiously because of the large amount of
missing data for both cases and controls.
Table 3 presents the association between daily alcohol intake
and invasive ovarian cancer risk in the Asian population adjusting for
age, smoking status, study and principal components. OR associated
with total alcohol intake of 0-7.6 g/d and 7.6-192.6 g/d among all
ovarian cancers were 0.92 (95% CI = 0.59-1.45) and 0.69 (95%
CI = 0.42-1.14), respectively (trend P = .188). No significant associa-
tions were observed for type of alcoholic beverage consumed. Anal-
yses that adjusted for several covariates listed in Table 2 showed
similar trends (data not shown). In addition, we carried out analyses
excluding younger subjects, non-drinkers, or Lys/Lys genotype, but
none of the results was substantially altered (data not shown).
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F IGURE 1 Genetic ancestry of Asians
in Ovarian Cancer Association Consortium
(OCAC) studies conducted in Asian
countries. Plot of the first 2 principal
components from each Asian ancestry
participant from a single study (blue circles)
superimposed over the first 2 principal
components from all Asian ancestry
participants that were genotyped in OCAC
(black circles). The black circles take the
form of countries denoting participants
with ancestrally similar allele frequencies.
A, JPN (Japan). B, SWH (Shanghai, China).
C, KRA (Korea). D, CHA (China)
F IGURE 2 Genetic ancestry of Asians
in Ovarian Cancer Association Consortium
(OCAC) studies conducted in the USA. Plot
of the first 2 principal components from
each Asian ancestry participant from a
single study (blue circles) superimposed
over the first 2 principal components from
all Asian ancestry participants that were
genotyped in OCAC (black circles).
Ancestral membership of Asian participants
in the US studies can be mapped to
country of origin. A, USC (California). B,
DOV (Washington). C, HAW (Hawaii)
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Table 4 presents the effect of ALDH2 rs671 genotypes and total
alcohol intake on invasive ovarian cancer risk overall in the Asian
population. No significant association between rs671 genotypes in
ALDH2 and invasive ovarian cancer risk overall was observed (OR
for dominant model = 0.92; 95% CI = 0.71-1.18; P = .490). No sig-
nificant interaction between any alcohol consumption and rs671 in
ALDH2 was observed (interaction P = .634).
Table 4 also presents associations between genotype and alco-
holic intake stratified by histological subtype. The Lys allele was sig-
nificantly inversely associated with both invasive mucinous (OR for
dominant model = 0.44; 95% CI = 0.20-0.97; P = .041) and invasive
plus borderline mucinous tumors (OR in dominant model = 0.48;
95% CI = 0.26-0.89; P = .018). We also included alcohol intake as a
covariate in this model, but none of the results was substantially
altered (invasive mucinous tumor: OR for dominant model = 0.46;
95% CI = 0.21-1.04; P = .062, invasive plus borderline mucinous
tumors: OR for dominant model = 0.46; 95% CI = 0.25-0.85;
P = .014). The test for heterogeneity for the association of the
ALDH2 Lys allele between the histological subtypes was not signifi-
cant (P-value for heterogeneity test = .20). There was no significant
association between alcoholic intake and ovarian cancer for any of
the histological subtypes. The OR associated with any alcohol intake
were less than 1 with the exception of invasive mucinous cancer.
TABLE 2 Characteristics of study subjects with invasive ovarian
cancer
Invasive cases
(N = 460) (%)
Controls
(N = 1274) (%) P-valuea
Histology
Serous 188 (40.9)
Mucinous 42 (9.1)
Endometrioid 75 (16.3)
Clear cell 69 (15.0)
Other epithelial 78 (17.0)
Non-epithelial 8 (1.7)
ALDH2 rs671 genotype
Glu/Glu 304 (66.1) 771 (60.5) .070
Glu/Lys 139 (30.2) 433 (34.0)
Lys/Lys 17 (3.7) 70 (5.5)
Total alcohol (grams per day)
None 372 (80.9) 1135 (89.1) <.001
0.1-7.6 54 (11.7) 67 (5.3)
7.6-192.6 28 (6.1) 67 (5.3)
Unknown 6 (1.3) 5 (0.4)
Smoking status
Never (%) 369 (80.2) 1133 (88.9) .051
Ever (%) 54 (11.7) 118 (9.3)
Unknown (%) 37 (8.0) 23 (1.8)
Age (y)
Median (range) 54.0 (23-85) 52.2 (19-88)
<40 (%) 43 (9.4) 44 (3.5) <.001
40-49 (%) 106 (23.0) 480 (37.7)
50-59 (%) 154 (33.5) 379 (29.8)
60-69 (%) 99 (21.5) 282 (22.1)
≥70 (%) 58 (12.6) 89 (7.0)
Education
Less than college
graduate (%)
123 (26.7) 157 (12.3) NE
More than college
graduate (%)
98 (21.3) 149 (11.7)
Unknown (%) 239 (52.0) 968 (76.0)
Body mass index
Median (range) 22.8 (16.7-39.8) 22.4 (16.4-34.0)
<25 kg/m2 (%) 134 (29.1) 130 (10.2) NE
≥25 kg/m2 (%) 42 (9.1) 32 (2.5)
Unknown (%) 284 (61.7) 1112 (87.3)
Age at menarche (y)
Median (range) 13 (9-21) 13 (9-22)
≤10 (%) 16 (3.5) 31 (2.4) NE
11-12 (%) 118 (25.7) 170 (13.3)
13-15 (%) 247 (53.7) 181 (14.2)
≥16 (%) 78 (17.0) 26 (2.0)
Unknown (%) 1 (0.2) 866 (68.0)
(Continues)
TABLE 2 (Continued)
Invasive cases
(N = 460) (%)
Controls
(N = 1274) (%) P-valuea
Oral contraception
Never (%) 216 (47.0) 222 (17.4) NE
Ever (%) 107 (23.3) 186 (14.6)
Unknown (%) 137 (29.8) 866 (68.0)
Tubal ligation
Yes (%) 42 (9.1) 68 (5.3) NE
No (%) 215 (46.7) 261 (20.5)
Unknown (%) 203 (44.1) 945 (74.2)
Parity
0 (%) 94 (20.4) 67 (5.3) NE
1-2 (%) 150 (32.6) 212 (16.6)
≥3 (%) 79 (17.2) 129 (10.1)
Unknown (%) 137 (29.8) 866 (68.0)
History of any prior cancers
No (%) 437 (95.0) 389 (30.5) NE
Yes (%) 19 (4.1) 21 (1.7)
Unknown (%) 4 (0.9) 864 (67.8)
History of breast or ovarian cancer in first-degree relatives
No (%) 104 (22.6) 104 (8.2) NE
Yes (%) 40 (8.7) 53 (4.2)
Unknown (%) 316 (68.7) 1117 (87.7)
aChi-squared test was performed except where there were a large num-
ber of missing observations.
NE, not estimated.
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There was no significant interaction with alcohol consumption with
any of the associations (Table S1).
We also carried out meta-analyses to calculate summary study-
specific estimates (Tables S2-S5). Overall, the results did not change
substantially, but the mucinous tumor cases were too few to calcu-
late a study-specific OR, and thus some studies were not included in
the meta-analyses.
4 | DISCUSSION
In the present study, we did not observe significant associations
between total alcohol intake and invasive ovarian cancer risk in
Asian populations. We found that the Lys allele of rs671 was associ-
ated with a decreased risk of both invasive mucinous ovarian cancer
and invasive plus borderline mucinous ovarian cancers, but not the
other histotypes, although the test for heterogeneity was not signifi-
cant. No significant interactions were observed between rs671 geno-
types in ALDH2 and alcohol intake with risk of invasive ovarian
cancer.
Results from epidemiological studies investigating the association
between alcohol drinking and ovarian cancer risk among Caucasians
are inconsistent, reporting either a null association,7-12 a positive
association,13,14 or negative associations.4-6 Alcohol has been
hypothesized to induce carcinogenesis by increasing the circulating
level of estrogens,52 oxidative stress, acetaldehyde, or depletion of
folate.53 In contrast, alcohol is reported to have a protective poten-
tial against ovarian carcinogenesis by decreasing follicle stimulating
hormone, luteinizing hormone and gonadotropin levels. Polyphenols
contained in red wine were proposed to explain the inverse associa-
tion observed between red wine and risk of ovarian cancer.5,6,10,54
We did not observe any statistically significant associations between
alcohol intake and ovarian cancer in the Asian participants in our
study. The evidence to support a role of alcohol in ovarian cancer
epidemiology in Asian populations is scarce and may warrant addi-
tional evaluation in larger studies.
The present analysis also examined ovarian cancer risk using the
functional ALDH2 rs671 polymorphism. The Lys allele acts as domi-
nant negative, because the variant form can suppress the activity of
the Glu allele by the formation of heterotetramers.24 Overall, 37.6%
of our study subjects were heterozygous or homozygous for the null
variant of ALDH2 rs671. Inactive ALDH2 results in prolonged expo-
sure to the metabolite, acetaldehyde, following alcohol intake. Peak
blood acetaldehyde concentrations post alcohol challenge are 18
times and 5 times higher among homozygous null variant and
heterozygous individuals compared with homozygous wild-type indi-
viduals.55 This renders the consumption of alcohol unpleasant
through inducing facial flushing, palpitations, drowsiness and other
symptoms. Consequently, the ALDH2 rs671 genotype has been used
as a surrogate for alcohol consumption in studies using the Men-
delian Randomization approach56,57 because its interpretation is not
influenced by confounding or bias that affects the interpretation of
self-reported alcohol intake. Therefore, it would be expected that
carriers of the Lys allele (null variant), which associates with low
alcohol intake, would be at lower risk of ovarian cancer, which is
what was observed in the current study for invasive mucinous ovar-
ian cancer and for combined invasive and borderline mucinous
TABLE 3 Association between alcoholic beverage and invasive
ovarian cancer risk among Asian population
Cases (N = 460) /
Controls (N = 1274) OR (95% CI) P-value
Total alcohol (g/d)a
None 372/1135 1 (ref.)
0-7.6 54/67 0.92 (0.59-1.45) .731
7.6-192.6 28/67 0.69 (0.42-1.14) .148
Unknown 6/5 NE
Beer (g/d)b
None 372/1135 1 (ref.)
0.2-5.3 21/32 0.84 (0.41-1.72) .637
5.3-136.9 18/32 1.01 (0.50-2.04) .724
Unknown 49/75 NE
Wine (g/d)b
None 372/1135 1 (ref.)
0.1-3.2 28/30 0.79 (0.36-1.75) .560
3.2-192.6 20/43 0.70 (0.32-1.51) .360
Unknown 40/66 NE
White wine (g/d)c,d
None 372/1135 1 (ref.)
0.2-3.2 15/20 0.60 (0.20-1.80) .358
3.2-192.6 11/32 0.61 (0.24-1.54) .299
Unknown 62/87 NE
Red wine (g/d)c,d
None 372/1135 1 (ref.)
0.2-3.1 17/28 0.45 (0.16-1.24) .124
3.1-92.9 9/22 0.60 (0.22-1.64) .321
Unknown 62/89 NE
Other alcoholic
beverage (g/d)b.e
None 372/1135 1 (ref.)
0.2-7.5 21/26 0.97 (0.46-2.06) .939
7.5-95.8 8/25 0.73 (0.28-1.94) .531
Unknown 59/88 NE
aOdds ratios (OR) are adjusted for age, smoking, principal component 1-5
and study site for total alcohol.
bOR for beer, wine, and other alcoholic beverages are mutually adjusted
in addition to age, smoking, principal component 1-5 and study site.
cOR for red wine and white wine are adjusted for beer and other alco-
holic beverages in addition to age, smoking, principal component 1-5 and
study site.
dIncluding AUS, DOV, HAW, and NEC.
eIncluding liquor, Japanese sake, Chuuhai and Shochu.
NE, not estimated.
AUS, Australia Ovarian Cancer Study & Australia Cancer Study (AOCS/
ACS); DOV, Diseases of the Ovary and their Evaluation (DOVE); HAW,
Hawaii Ovarian Cancer Study; NEC, New England-based Case-Control
Study of Ovarian Cancer (NECC).
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cancer (OR = 0.48, P = .018). This implies that alcohol consumption
may be associated with increased risk of mucinous ovarian cancer.
The strengths of this investigation include the analysis of individ-
ual-level data from a relatively large sample compared to previous
studies, which allowed us to quantify risk associations of the ALDH2
polymorphism, detailed drinking status and ovarian cancer risk. Other
strengths are the uniform genotyping procedures and quality-control
measures adopted. We were also able to control for population
stratification by first using LAMP analysis to identify Asian ancestral
membership separate from other genetically similar groups, and then
including 5 principal components as model covariates to control for
residual genetic heterogeneity within the Asian membership.
The present study does have some weaknesses. The models for
alcohol intake did not adjust for all potential confounders, because a
substantial number of subjects from a single study (SWH) had miss-
ing values for several covariates. Further, the self-reported alcohol
quantities were either too low or measured with error and may have
obscured an association with ovarian cancer if it existed whereas the
genetic models are not influenced by these limitations. Despite the
common prevalence of the ALDH2 polymorphism among Asians, the
small sample sizes for the histological type analysis precludes a con-
clusive interpretation of the results for Mendelian Randomization,
which must await further study with a larger sample size. Finally, we
did not adjust for multiple comparisons and a cautious interpretation
of the histologically specific results is required.
In conclusion, we observed an inverse association between the
Lys allele of rs671 in ALDH2 and mucinous ovarian cancer risk in an
Asian population. Because the rs671 Lys allele causes ALDH2 inacti-
vation leading to increased acetaldehyde exposure, the observed
inverse genetic association with mucinous ovarian cancer is inferred
to mean that alcohol intake may be a risk factor for this histotype.
Future investigation using even larger epidemiological studies of
Asians is warranted.
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